Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $27.80 Consensus Price Target from Analysts

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have received a consensus rating of “Buy” from the seven ratings firms that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation, three have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $27.80.

TBPH has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Theravance Biopharma in a research note on Thursday, January 22nd. BTIG Research reaffirmed a “buy” rating and set a $40.00 price target on shares of Theravance Biopharma in a research note on Tuesday, February 3rd. Wall Street Zen downgraded Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. HC Wainwright increased their price target on Theravance Biopharma from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Finally, Oppenheimer assumed coverage on Theravance Biopharma in a report on Wednesday, December 3rd. They issued an “outperform” rating and a $27.00 price objective for the company.

Theravance Biopharma Stock Performance

TBPH opened at $19.51 on Monday. The stock has a market cap of $988.57 million, a price-to-earnings ratio of 34.23 and a beta of 0.15. The firm’s fifty day moving average is $19.10 and its 200 day moving average is $16.14. Theravance Biopharma has a fifty-two week low of $7.90 and a fifty-two week high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.10. Theravance Biopharma had a net margin of 36.53% and a return on equity of 12.20%. The firm had revenue of $19.99 million for the quarter, compared to analysts’ expectations of $19.89 million. On average, equities research analysts predict that Theravance Biopharma will post -1.09 earnings per share for the current year.

Insider Transactions at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of Theravance Biopharma stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $18.75, for a total value of $582,506.25. Following the transaction, the senior vice president directly owned 277,695 shares of the company’s stock, valued at approximately $5,206,781.25. The trade was a 10.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.90% of the stock is owned by company insiders.

Institutional Trading of Theravance Biopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TBPH. Quarry LP acquired a new stake in Theravance Biopharma in the 3rd quarter valued at $26,000. Caitong International Asset Management Co. Ltd lifted its holdings in Theravance Biopharma by 107.4% during the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 1,411 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Theravance Biopharma by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 515 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Theravance Biopharma by 18.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 781 shares in the last quarter. Finally, CIBC Private Wealth Group LLC increased its stake in shares of Theravance Biopharma by 20,269.6% during the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 4,662 shares in the last quarter. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.